Who are ZOSTAVAX™ (Nonconcomitant)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): varicella-5, SKYVaricella®, Varicella Vaccine, MMR vaccination, Zoster Vaccine Live, Mumps vaccine, Live (MV).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zostavax-nonconcomitant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ZOSTAVAX™ (Nonconcomitant) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ZOSTAVAX™ (Nonconcomitant) (ZOSTAVAX™ (Nonconcomitant)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Varicella-zoster virus (VZV) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

ZOSTAVAX™ (Nonconcomitant) (ZOSTAVAX™ (Nonconcomitant)) — Merck Sharp & Dohme LLC. ZOSTAVAX is a live attenuated vaccine that stimulates the immune system to prevent herpes zoster (shingles) by boosting varicella-zoster virus (VZV)-specific cell-mediated immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ZOSTAVAX™ (Nonconcomitant) TARGET	ZOSTAVAX™ (Nonconcomitant)	Merck Sharp & Dohme LLC	phase 3	Live attenuated vaccine	Varicella-zoster virus (VZV)
varicella-5	varicella-5	Changchun Keygen Biological Products Co., Ltd.	marketed	Live attenuated vaccine	Varicella-zoster virus
SKYVaricella®	SKYVaricella®	SK Bioscience Co., Ltd.	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Varicella Vaccine	Varicella Vaccine	Novartis	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
MMR vaccination	MMR vaccination	Klara M. Pósfay Barbe	marketed	Live attenuated vaccine
Zoster Vaccine Live	Zoster Vaccine Live	Merck Sharp & Dohme LLC	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Mumps vaccine, Live (MV)	Mumps vaccine, Live (MV)	Sinovac Biotech Co., Ltd	marketed	Live attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ZOSTAVAX™ (Nonconcomitant) — Competitive Intelligence Brief. https://druglandscape.com/ci/zostavax-nonconcomitant. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing